The Pulmonary Sarcoidosis drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Sarcoidosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Sarcoidosis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Pulmonary Sarcoidosis by ten companies/universities/institutes. The top development phase for Pulmonary Sarcoidosis is phase ii with five drugs in that stage. The Pulmonary Sarcoidosis pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pulmonary Sarcoidosis pipeline products market are: Novartis, Molecure and OrphAI Therapeutics.
The key targets in the Pulmonary Sarcoidosis pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Serum Amyloid A (SAA), and Vasoactive Intestinal Polypeptide Receptor 1 (Pituitary Adenylate Cyclase Activating Polypeptide Type II Receptor or VPAC1 or VIPR1).
The key mechanisms of action in the Pulmonary Sarcoidosis pipeline product include DNA Synthesis Inhibitor with one drug in Preclinical. The Pulmonary Sarcoidosis pipeline products include five routes of administration with the top ROA being Intravenous and five key molecule types in the Pulmonary Sarcoidosis pipeline products market including Monoclonal Antibody, and Small Molecule.
Pulmonary Sarcoidosis overview
Pulmonary Sarcoidosis is a rare inflammatory disease that affects the multi-organs predominantly lungs and intrathoracic lymph nodes. It is characterized by the presence of granulomas in which group of cells form clusters of inflamed tissue. Younger and middle-aged groups are commonly affected and there is no specific origin causing this condition. It is differentiated into five different stages from stage 0 to stage 4. Commonly presented with respiratory symptoms of SOB, lumps on skin, dry cough, dyspnea, and with neurological and cardiac symptoms. PFT, Chest radiography, CT scan are common diagnostic tests done. Generally, no treatment is required as the condition gets subsided but as a supportive care steroids, anti-analgesics are prescribed.
For a complete picture of Pulmonary Sarcoidosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
